KR20240142567A - 중수소화 또는 부분적 중수소화 n,n-다이메틸트립타민 화합물을 포함하는 치료 조성물 - Google Patents
중수소화 또는 부분적 중수소화 n,n-다이메틸트립타민 화합물을 포함하는 치료 조성물 Download PDFInfo
- Publication number
- KR20240142567A KR20240142567A KR1020247030292A KR20247030292A KR20240142567A KR 20240142567 A KR20240142567 A KR 20240142567A KR 1020247030292 A KR1020247030292 A KR 1020247030292A KR 20247030292 A KR20247030292 A KR 20247030292A KR 20240142567 A KR20240142567 A KR 20240142567A
- Authority
- KR
- South Korea
- Prior art keywords
- dimethyltryptamine
- composition
- compounds
- dideutero
- deuterated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1907871.6A GB201907871D0 (en) | 2019-06-03 | 2019-06-03 | Therapeutic compositions |
| GB1907871.6 | 2019-06-03 | ||
| PCT/EP2020/065244 WO2020245133A1 (en) | 2019-06-03 | 2020-06-02 | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| KR1020217043410A KR20220034061A (ko) | 2019-06-03 | 2020-06-02 | 중수소화 또는 부분적 중수소화 n,n-다이메틸트립타민 화합물을 포함하는 치료 조성물 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217043410A Division KR20220034061A (ko) | 2019-06-03 | 2020-06-02 | 중수소화 또는 부분적 중수소화 n,n-다이메틸트립타민 화합물을 포함하는 치료 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240142567A true KR20240142567A (ko) | 2024-09-30 |
Family
ID=67385960
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247030292A Ceased KR20240142567A (ko) | 2019-06-03 | 2020-06-02 | 중수소화 또는 부분적 중수소화 n,n-다이메틸트립타민 화합물을 포함하는 치료 조성물 |
| KR1020217043410A Ceased KR20220034061A (ko) | 2019-06-03 | 2020-06-02 | 중수소화 또는 부분적 중수소화 n,n-다이메틸트립타민 화합물을 포함하는 치료 조성물 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217043410A Ceased KR20220034061A (ko) | 2019-06-03 | 2020-06-02 | 중수소화 또는 부분적 중수소화 n,n-다이메틸트립타민 화합물을 포함하는 치료 조성물 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11771681B2 (https=) |
| EP (2) | EP3826632B1 (https=) |
| JP (1) | JP7523474B2 (https=) |
| KR (2) | KR20240142567A (https=) |
| CN (1) | CN114096246B (https=) |
| AU (1) | AU2020286709B2 (https=) |
| BR (1) | BR112021024333A2 (https=) |
| CA (2) | CA3142290C (https=) |
| DK (1) | DK3826632T3 (https=) |
| EA (1) | EA202193338A1 (https=) |
| ES (1) | ES2922101T3 (https=) |
| GB (4) | GB201907871D0 (https=) |
| HR (1) | HRP20220837T8 (https=) |
| HU (1) | HUE059439T2 (https=) |
| IL (1) | IL288617B2 (https=) |
| MX (1) | MX2021014728A (https=) |
| PL (1) | PL3826632T3 (https=) |
| PT (1) | PT3826632T (https=) |
| TW (1) | TWI860478B (https=) |
| WO (1) | WO2020245133A1 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| JP7422473B2 (ja) * | 2019-11-07 | 2024-01-26 | サイビン ユーケー リミテッド | 合成方法 |
| MX2022009528A (es) | 2020-02-04 | 2022-11-14 | Mindset Pharma Inc | Derivados de 3-pirrolidina-indol como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc. |
| PH12022551981A1 (en) | 2020-02-04 | 2023-10-16 | Mindset Pharma Inc | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
| AU2021268204A1 (en) | 2020-05-08 | 2022-12-08 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
| KR20240096817A (ko) | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| EP3902541B1 (en) * | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| AU2021204158B2 (en) * | 2020-06-02 | 2023-03-02 | Cybin Uk Ltd | Deuterated compounds |
| GB2605144A (en) * | 2021-03-22 | 2022-09-28 | Small Pharma Ltd | Deuterated compounds |
| US12122741B2 (en) | 2020-08-18 | 2024-10-22 | Cybin Irl Limited | Therapeutic phenethylamine compositions and methods of use |
| WO2022043227A1 (en) * | 2020-08-28 | 2022-03-03 | Small Pharma Ltd | Injectable formulation |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| IL303288A (en) | 2020-12-01 | 2023-07-01 | Small Pharma Ltd | N,N-Dimethyltryptamine compounds partially or fully deuterated |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| US12521370B2 (en) | 2020-12-01 | 2026-01-13 | Cybin Uk Ltd | Inhalable formulations |
| WO2022120181A1 (en) * | 2020-12-03 | 2022-06-09 | Mydecine Innovations Group Inc. | Novel psilocin analog compositions and methods of synthesizing the same |
| AU2022229037A1 (en) * | 2021-03-02 | 2023-09-28 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
| US20230136824A1 (en) | 2021-04-26 | 2023-05-04 | ATAI Life Sciences AG | N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof |
| MX2023012651A (es) * | 2021-04-26 | 2023-11-06 | Atai Therapeutics Inc | Novedosas composiciones y metodos de n,n-dimetiltriptamina. |
| IL308184A (en) * | 2021-05-05 | 2024-01-01 | Kare Chemical Tech Inc | Processes for the preparation of catalytic tryptamines and starting materials |
| JP2024522065A (ja) * | 2021-05-17 | 2024-06-11 | サイビン アイアールエル リミテッド | シロシビンの製剤 |
| IL308816A (en) * | 2021-05-25 | 2024-01-01 | Atai Therapeutics Inc | New n,n-dimethyltryptamine salts and crystalline salt forms |
| EP4347559A4 (en) * | 2021-06-02 | 2025-04-09 | Saint Joseph's University | FLUORINATED TRYPTAMINE COMPOUNDS, RELATED ANALOGUES AND METHODS USING THEM |
| MX2023014620A (es) | 2021-06-09 | 2024-01-30 | Atai Therapeutics Inc | Nuevos profarmacos y conjugados de dimetiltriptamina. |
| WO2023018864A1 (en) | 2021-08-12 | 2023-02-16 | Psilosterics, Llc | Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same |
| IL311050A (en) | 2021-08-23 | 2024-04-01 | Alexander Shulgin Res Institute Inc | Deuterated empathogens |
| IL311051A (en) * | 2021-08-23 | 2024-05-01 | Alexander Shulgin Res Institute Inc | Fluorinated empathogens |
| US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| EP4159201A1 (en) | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Encapsulated microparticles and nanoparticles of dimethyltriptamines |
| EP4159192A1 (en) | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders |
| US20250002457A1 (en) * | 2021-10-29 | 2025-01-02 | Psilera Inc. | N,n-dimethyltryptamine (dmt) crystalline products and methods of making the same |
| MX2024005955A (es) | 2021-11-18 | 2024-06-11 | Cybin Uk Ltd | Formulaciones inyectables e inhalables. |
| US12318477B2 (en) | 2021-11-18 | 2025-06-03 | Cybin Uk Ltd | Injectable and inhalable formulations |
| JP2024545787A (ja) | 2021-12-30 | 2024-12-11 | アタイ セラピューティクス， インコーポレイテッド | 一酸化窒素送達剤としてのジメチルトリプタミン類似体 |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| AU2023246690A1 (en) * | 2022-03-31 | 2024-11-07 | Cybin Irl Limited | Methods for delivery of psychedelic medications by inhalation and systems for performing the methods |
| EP4522167A1 (en) | 2022-05-10 | 2025-03-19 | Mydecine Innovations Group Inc. | Novel psilocin prodrug compounds and methods of synthesizing the same |
| EP4618981A1 (en) | 2022-11-17 | 2025-09-24 | Remedi, Inc. | Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use |
| AU2024242138A1 (en) | 2023-03-31 | 2025-11-13 | Cybin Uk Ltd | Combination comprising a monoamine antidepressant agent and a short-duration psychedelic agent |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
| WO2026013174A1 (en) | 2024-07-10 | 2026-01-15 | Cybin Uk Ltd | Pharmaceutical compositions comprising deuterated n,n-dimethyltryptamine |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4336378A (en) | 1980-04-10 | 1982-06-22 | Sandoz, Inc. | Isoxazolyl indolamines |
| EP0593513B1 (en) | 1991-06-21 | 1998-10-28 | Smithkline Beecham Plc | Tryptamine analogues, their synthesis and their use as 5-ht1-like receptors or 5-ht2 receptor agonistes |
| US6376531B1 (en) | 1998-11-13 | 2002-04-23 | Rupert Charles Bell | Method of treatment using deuterium compounds |
| EP2036540A3 (en) | 2000-06-16 | 2009-12-16 | Jagotec AG | Improved injectable dispersions of propofol |
| ITRM20010356A1 (it) | 2001-06-21 | 2002-12-23 | Sigma Tau Ind Farmaceuti | "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina. |
| WO2004085392A1 (en) | 2003-03-25 | 2004-10-07 | Faust Pharmaceuticals | Melatonin derivatives and their use for treating neurological dysfunctions |
| JP2010507585A (ja) | 2006-10-19 | 2010-03-11 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 置換インドール |
| WO2008071455A1 (en) | 2006-12-15 | 2008-06-19 | Bayer Schering Pharma Aktiengesellschaft | Bicyclic acyltryptophanols |
| CZ302424B6 (cs) | 2007-06-13 | 2011-05-11 | Zentiva, A. S. | Zpusob prípravy almotriptanu o vysoké cistote |
| US20090076121A1 (en) | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched sumatriptan |
| US20090093513A1 (en) | 2007-10-09 | 2009-04-09 | Hamann Mark T | Method to Use Compositions Having Antidepressant Anxiolytic and Other Neurological Activity and Compositions of Matter |
| US20100069399A1 (en) * | 2008-09-15 | 2010-03-18 | Auspex Pharmaceutical, Inc. | Arylpiperazine modulators of d2 receptors, 5-ht1a receptors, and/or 5-ht2a receptors |
| JP6367545B2 (ja) | 2013-12-17 | 2018-08-01 | コンサート ファーマシューティカルズ インコーポレイテッド | ルキソリチニブの重水素化誘導体 |
| WO2018064465A1 (en) | 2016-09-29 | 2018-04-05 | The Regents Of The University Of California | Compounds for increasing neural plasticity |
| CA3052974A1 (en) | 2017-02-09 | 2018-08-16 | CaaMTech, LLC | Compositions and methods comprising a psilocybin derivative |
| US20200147038A1 (en) | 2017-04-20 | 2020-05-14 | Eleusis Benefit Corporation, Pbc | Assessing and treating psychedelic-responsive subjects |
| CN109251151A (zh) * | 2017-07-12 | 2019-01-22 | 北京广为医药科技有限公司 | N-(2-(取代-萘-1-基)乙基)取代酰胺类化合物、其制备及其用途 |
| MA50786A (fr) * | 2017-10-26 | 2022-04-27 | Blumentech S L | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
| WO2019089902A1 (en) | 2017-11-01 | 2019-05-09 | Drexel University | Compounds, compositions, and methods for treating diseases |
| EP4353314A3 (en) | 2019-02-22 | 2024-07-03 | GH Research Ireland Limited | 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for treating major depression |
| MD3927338T2 (ro) | 2019-02-22 | 2025-03-31 | Gh Res Ireland Limited | Compoziții cuprinzând 5-metoxi-N,N-dimetiltriptamină (5-MeO-DMT) pentru utilizare în tratarea tulburărilor mentale |
| CN113784962B (zh) | 2019-02-27 | 2025-04-25 | 加利福尼亚大学董事会 | 用于治疗脑部疾病的氮杂环庚三烯并-吲哚类和其他杂环 |
| AU2020228289B2 (en) | 2019-02-27 | 2026-02-05 | The Regents Of The University Of California | N-substituted indoles and other heterocycles for treating brain disorders |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| JP7422473B2 (ja) | 2019-11-07 | 2024-01-26 | サイビン ユーケー リミテッド | 合成方法 |
| PH12022551981A1 (en) | 2020-02-04 | 2023-10-16 | Mindset Pharma Inc | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
| WO2021234608A1 (en) | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| KR20240096817A (ko) | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| EP3902541B1 (en) | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| GB202008961D0 (en) | 2020-06-12 | 2020-07-29 | Beckley Psytech Ltd | Pharmaceutical composition |
| CN116056705A (zh) | 2020-08-05 | 2023-05-02 | 巴塞尔大学医院 | 用于dmt辅助心理疗法的静脉内dmt施用方法 |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| WO2022043227A1 (en) | 2020-08-28 | 2022-03-03 | Small Pharma Ltd | Injectable formulation |
| US20220062237A1 (en) | 2020-08-28 | 2022-03-03 | Small Pharma Ltd | Injectable formulation |
| JP2023544724A (ja) | 2020-10-02 | 2023-10-25 | サイビン アイアールエル リミテッド | 吸入による幻覚発動薬の送達方法および方法を実施するためのシステム |
| US11000534B1 (en) | 2020-10-08 | 2021-05-11 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
| IL303288A (en) | 2020-12-01 | 2023-07-01 | Small Pharma Ltd | N,N-Dimethyltryptamine compounds partially or fully deuterated |
| US12521370B2 (en) | 2020-12-01 | 2026-01-13 | Cybin Uk Ltd | Inhalable formulations |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| US12318477B2 (en) | 2021-11-18 | 2025-06-03 | Cybin Uk Ltd | Injectable and inhalable formulations |
-
2019
- 2019-06-03 GB GBGB1907871.6A patent/GB201907871D0/en not_active Ceased
-
2020
- 2020-06-02 EP EP20731372.7A patent/EP3826632B1/en active Active
- 2020-06-02 BR BR112021024333A patent/BR112021024333A2/pt unknown
- 2020-06-02 ES ES20731372T patent/ES2922101T3/es active Active
- 2020-06-02 HU HUE20731372A patent/HUE059439T2/hu unknown
- 2020-06-02 EA EA202193338A patent/EA202193338A1/ru unknown
- 2020-06-02 CN CN202080050439.9A patent/CN114096246B/zh active Active
- 2020-06-02 MX MX2021014728A patent/MX2021014728A/es unknown
- 2020-06-02 DK DK20731372.7T patent/DK3826632T3/da active
- 2020-06-02 PL PL20731372.7T patent/PL3826632T3/pl unknown
- 2020-06-02 WO PCT/EP2020/065244 patent/WO2020245133A1/en not_active Ceased
- 2020-06-02 US US16/890,664 patent/US11771681B2/en active Active
- 2020-06-02 GB GB2107702.9A patent/GB2592822B/en active Active
- 2020-06-02 CA CA3142290A patent/CA3142290C/en active Active
- 2020-06-02 IL IL288617A patent/IL288617B2/en unknown
- 2020-06-02 GB GB2100807.3A patent/GB2586940B/en active Active
- 2020-06-02 JP JP2021571882A patent/JP7523474B2/ja active Active
- 2020-06-02 GB GB2008303.6A patent/GB2585978B/en active Active
- 2020-06-02 KR KR1020247030292A patent/KR20240142567A/ko not_active Ceased
- 2020-06-02 HR HRP20220837TT patent/HRP20220837T8/hr unknown
- 2020-06-02 EP EP22173907.1A patent/EP4062910B1/en active Active
- 2020-06-02 US US17/616,345 patent/US12076311B2/en active Active
- 2020-06-02 PT PT207313727T patent/PT3826632T/pt unknown
- 2020-06-02 KR KR1020217043410A patent/KR20220034061A/ko not_active Ceased
- 2020-06-02 AU AU2020286709A patent/AU2020286709B2/en active Active
- 2020-12-23 CA CA3104072A patent/CA3104072C/en active Active
-
2021
- 2021-06-01 TW TW110119792A patent/TWI860478B/zh active
-
2024
- 2024-07-22 US US18/779,611 patent/US20240374565A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20240142567A (ko) | 중수소화 또는 부분적 중수소화 n,n-다이메틸트립타민 화합물을 포함하는 치료 조성물 | |
| JP7579888B2 (ja) | 治療用固形製剤 | |
| US12042564B2 (en) | Therapeutic solid dosage forms | |
| US20230086574A1 (en) | 5-methoxy-n,n-dimethyltryptamine crystalline forms | |
| US20220169606A1 (en) | Compositions and compounds for bioanalysis | |
| HK40060891A (en) | Therapeutic compositions | |
| HK40081622A (en) | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds | |
| EA046951B1 (ru) | Терапевтические композиции, включающие дейтерированные или частично дейтерированные соединения n,n-диметилтриптамина | |
| HK40045846A (en) | Therapeutic compositions | |
| US20240342101A1 (en) | Therapeutic solid dosage forms | |
| HK40064531A (en) | Therapeutic solid dosage forms | |
| HK40120570A (en) | Therapeutic solid dosage forms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A18-div-PA0104 St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PA0302 | Request for accelerated examination |
St.27 status event code: A-1-2-D10-D17-exm-PA0302 St.27 status event code: A-1-2-D10-D16-exm-PA0302 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| B15 | Application refused following examination |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |